Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study renews breast ca link to migraines

August 25, 2009
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

In a follow-up study, Christopher I. Li, MD, PhD, and colleagues have reconfirmed their finding that migraine headaches are associated with a lower risk of breast cancer.

In a follow-up study, Christopher I. Li, MD, PhD, and colleagues have reconfirmed their finding that migraine headaches are associated with a lower risk of breast cancer.

In the newest research, Dr. Li and his group at Fred Hutchinson Cancer Research Center in Seattle found that the risk reduction remained statistically similar regardless of a woman’s menopausal status, her age at migraine diagnosis, use of prescription migraine medications, or whether she avoided known migraine triggers such as alcohol consumption, smoking, and taking hormone replacement.

These triggers are also well-established breast cancer risk factors. What remains unknown is why this link exists (Cancer Epidemiol Biomarkers Prev 18:2030-2034, 2009; 17:3116-3122, 2008).

Articles in this issue

New Doxil-based regimens don’t fly with FDA advisors
Four steps to improve the profitability of your oncology practice
Mathematical model predicts resistance to Herceptin
ASTRO issues guide on accelerated breast radiotherapy
Study renews breast ca link to migraines
Sutent shows promise for brain metastases in NSCLC patients
Abraxane, carboplatin pack one-two punch in two types of lung cancer
Discord prevails over pt privacy in clinical trials
Gastric adenocarcinoma: How to choose between postoperative chemoradiation and perioperative Rx?
Venous thrombotic events elevate chance of death in ALL, but no risk seen with AML
Expert panel reviews strategies for nutrition and cancer care
Office of Oncology Drug Products: A step ahead of the Obama transparency curve
Post-Rx surgery won’t boost OS in lung cancer
Siemens debuts RT plan platform
Exposure to pesticides raises myeloma risk

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

Keerthana Sureshkumar;Richa Dawar
July 10th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Siya Patil;Emily Rooney;Hemal Grover;Christine Chen
July 8th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

Roman Fabbricatore
July 8th 2025
Article

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.


12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi
July 7th 2025
Article
Related Content

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

Keerthana Sureshkumar;Richa Dawar
July 10th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Siya Patil;Emily Rooney;Hemal Grover;Christine Chen
July 8th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

Roman Fabbricatore
July 8th 2025
Article

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.


12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi
July 7th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.